Clinical relevance and therapeutic potential of IL-38 in immune and non-immune-related disorders
暂无分享,去创建一个
[1] G. Palmer,et al. Multifaceted roles of IL-38 in inflammation and cancer. , 2022, Cytokine.
[2] E. Fröhlich. Acute Respiratory Distress Syndrome: Focus on Viral Origin and Role of Pulmonary Lymphatics , 2021, Biomedicines.
[3] Zhongxin Lu,et al. Interleukin-38 Suppresses Cell Migration and Proliferation and Promotes Apoptosis of Colorectal Cancer Cell Through Negatively Regulating Extracellular Signal-Regulated Kinases Signaling. , 2021, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[4] W. Jiskoot,et al. The interleukin-1 cytokine family members: Role in cancer pathogenesis and potential therapeutic applications in cancer immunotherapy. , 2021, Cytokine & growth factor reviews.
[5] R. Bellomo,et al. Mast Cell Cytokines IL-1, IL-33, and IL-36 Mediate Skin Inflammation in Psoriasis: A Novel Therapeutic Approach with the Anti-Inflammatory Cytokines IL-37, IL-38, and IL-1Ra , 2021, International journal of molecular sciences.
[6] Lei Zhao,et al. The emerging role of Interleukin 37 in bone homeostasis and inflammatory bone diseases. , 2021, International immunopharmacology.
[7] M. Iannacone,et al. Immunobiology and pathogenesis of hepatitis B virus infection , 2021, Nature Reviews Immunology.
[8] Xiaofang Wang,et al. The Role of IL-36 in Infectious Diseases: Potential Target for COVID-19? , 2021, Frontiers in Immunology.
[9] W. Xiao,et al. IL-38 exerts anti-inflammatory and anti-fibrotic effects in thyroid-associated ophthalmopathy. , 2021, The Journal of clinical endocrinology and metabolism.
[10] D. Wolf,et al. Inflammatory Cell Recruitment in Cardiovascular Disease , 2021, Frontiers in Cell and Developmental Biology.
[11] B. Brüne,et al. IL-38 Ablation Reduces Local Inflammation and Disease Severity in Experimental Autoimmune Encephalomyelitis , 2021, The Journal of Immunology.
[12] C. Lam,et al. Interleukin-38 ameliorates poly(I:C) induced lung inflammation: therapeutic implications in respiratory viral infections , 2021, Cell death & disease.
[13] W. Su,et al. Elevated IL-38 inhibits IL-23R expression and IL-17A production in thyroid-associated ophthalmopathy. , 2020, International immunopharmacology.
[14] J. Sabbatinelli,et al. Plasma levels of interleukin-38 in healthy aging and in type 2 diabetes. , 2020, Diabetes research and clinical practice.
[15] M. Khan. Regulatory T cells mediated immunomodulation during asthma: a therapeutic standpoint , 2020, Journal of translational medicine.
[16] J. Laffey,et al. Role of the adaptive immune response in sepsis , 2020, Intensive Care Medicine Experimental.
[17] S. Smeekens,et al. Human recombinant interleukin-38 suppresses inflammation in mouse models of local and systemic disease. , 2020, Cytokine.
[18] M. Nazarinia,et al. Elevated IL-38 Serum Levels in Newly Diagnosed Multiple Sclerosis and Systemic Sclerosis Patients , 2020, Medical Principles and Practice.
[19] Xiaoping Zhou,et al. IL‐38: A novel cytokine in systemic lupus erythematosus pathogenesis , 2020, Journal of cellular and molecular medicine.
[20] Hongtao Wang,et al. Blockade of Th17 response by IL-38 in primary Sjögren's syndrome. , 2020, Molecular immunology.
[21] M. Akiyama,et al. IL-36 receptor antagonist deficiency resulted in delayed wound healing due to excessive recruitment of immune cells , 2020, Scientific Reports.
[22] A. Yalcin,et al. Future perspective: biologic agents in patients with severe COVID-19 , 2020, Immunopharmacology and immunotoxicology.
[23] Yan Li,et al. Interleukin‐38 inhibits adipogenesis and inflammatory cytokine production in 3T3‐L1 preadipocytes , 2020, Cell biology international.
[24] K. Kosai,et al. Interleukin-38 promotes tumor growth through regulation of CD8+ tumor-infiltrating lymphocytes in lung cancer tumor microenvironment , 2020, Cancer Immunology, Immunotherapy.
[25] S. Leeman,et al. IL-38 inhibits microglial inflammatory mediators and is decreased in amygdala of children with autism spectrum disorder , 2020, Proceedings of the National Academy of Sciences.
[26] Zhiwei Xu,et al. Interleukin-38 overexpression prevents bleomycin-induced mouse pulmonary fibrosis , 2020, Naunyn-Schmiedeberg's Archives of Pharmacology.
[27] Yuan Tian,et al. Interleukin‐36 receptor antagonist attenuates atherosclerosis development by inhibiting NLRP3 inflammasome , 2020, Journal of cellular physiology.
[28] P. Conti,et al. Advances in Mast Cell Activation by IL-1 and IL-33 in Sjögren’s Syndrome: Promising Inhibitory Effect of IL-37 , 2020, International journal of molecular sciences.
[29] Hong Liu,et al. High Expression of ACE2 on Keratinocytes Reveals Skin as a Potential Target for SARS-CoV-2 , 2020, Journal of Investigative Dermatology.
[30] B. Lipworth,et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 , 2020, Journal of Allergy and Clinical Immunology.
[31] Lei Cheng,et al. IL-38 alleviates the inflammatory response and the degeneration of nucleus pulposus cells via inhibition of the NF-κB signaling pathway in vitro. , 2020, International immunopharmacology.
[32] W. Xiao,et al. IL-38 restrains inflammatory response of collagen-induced arthritis in rats via SIRT1/HIF-1α signaling pathway , 2020, Bioscience reports.
[33] Zhe Zhu,et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019 , 2020, International Journal of Infectious Diseases.
[34] Fang Liu,et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 , 2020, Journal of Clinical Virology.
[35] Gianpaolo Ronconi,et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. , 2020 .
[36] Tao Chen,et al. Interleukin-38 increases the insulin sensitivity in children with the type 2 diabetes. , 2020, International immunopharmacology.
[37] Jing Li,et al. Interleukin-36 receptor antagonist alleviates airway inflammation in asthma via inhibiting the activation of Interleukin-36 pathway. , 2020, International immunopharmacology.
[38] X. Hou,et al. Interleukin-38 is elevated in inflammatory bowel diseases and suppresses intestinal inflammation. , 2020, Cytokine.
[39] M. Jaeger,et al. Reduced concentrations of the B cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects , 2019, European journal of immunology.
[40] Yun Ge,et al. Interleukin‐38 protects against sepsis by augmenting immunosuppressive activity of CD4+CD25+ regulatory T cells , 2019, Journal of cellular and molecular medicine.
[41] F. Zhang,et al. Interleukin-38 in colorectal cancer: a potential role in precision medicine , 2019, Cancer Immunology, Immunotherapy.
[42] R. Zhu,et al. Interleukin‐38 alleviates cardiac remodelling after myocardial infarction , 2019, Journal of cellular and molecular medicine.
[43] Chuanjiang Wang,et al. IL-38 is a biomarker for acute respiratory distress syndrome in humans and down-regulates Th17 differentiation in vivo. , 2019, Clinical immunology.
[44] E. Cheung,et al. Anti-inflammatory mechanisms of the novel cytokine interleukin-38 in allergic asthma , 2019, Cellular & Molecular Immunology.
[45] S. Zheng,et al. IL-38: A New Player in Inflammatory Autoimmune Disorders , 2019, Biomolecules.
[46] Yuxia Zhao,et al. Molecular mechanisms of interleukin-38 inhibiting inflammatory bowel disease in children by regulating nuclear factor-κB and signal transduction and activator of transcription 3 pathway , 2019 .
[47] B. Brüne,et al. IL-38 Ameliorates Skin Inflammation and Limits IL-17 Production from γδ T Cells. , 2019, Cell reports.
[48] S. Seyedian,et al. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease , 2019, Journal of medicine and life.
[49] C. Pitzalis,et al. IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential , 2019, International journal of molecular sciences.
[50] Yong-ming Yao,et al. Recent advances in the biology of IL-1 family cytokines and their potential roles in development of sepsis. , 2019, Cytokine & growth factor reviews.
[51] T. Kinoshita,et al. Attenuated Airway Eosinophilic Inflammations in IL-38 Knockout Mouse Model. , 2018, The Kurume medical journal.
[52] Yan Li,et al. Hydrodynamic delivery of IL-38 gene alleviates obesity-induced inflammation and insulin resistance. , 2019, Biochemical and biophysical research communications.
[53] J. Yamamoto-Furusho,et al. Differential Expression of IL-36 Family Members and IL-38 by Immune and Nonimmune Cells in Patients with Active Inflammatory Bowel Disease , 2018, BioMed research international.
[54] E. Eisenmesser,et al. IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment , 2018, Cell Death & Disease.
[55] L. Su,et al. Plasma interleukin‐38 in patients with rheumatoid arthritis , 2018, International immunopharmacology.
[56] Jingyu Yang,et al. Elevated Interleukin-38 Level Associates with Clinical Response to Atorvastatin in Patients with Hyperlipidemia , 2018, Cellular Physiology and Biochemistry.
[57] Yibing Yin,et al. Interleukin 38 Protects Against Lethal Sepsis , 2018, The Journal of infectious diseases.
[58] G. Palmer,et al. The severity of imiquimod-induced mouse skin inflammation is independent of endogenous IL-38 expression , 2018, PloS one.
[59] B. Le Goff,et al. The enigmatic role of IL-38 in inflammatory diseases. , 2018, Cytokine & growth factor reviews.
[60] Giou-Teng Yiang,et al. New Insights into the Immune Molecular Regulation of the Pathogenesis of Acute Respiratory Distress Syndrome , 2018, International journal of molecular sciences.
[61] C. Gabay,et al. Regulation and function of interleukin‐36 cytokines , 2018, Immunological reviews.
[62] L. Joosten,et al. Biology of IL‐38 and its role in disease , 2018, Immunological reviews.
[63] C. Dinarello. Overview of the IL‐1 family in innate inflammation and acquired immunity , 2018, Immunological reviews.
[64] Liwei Lu,et al. IL-36 cytokines in autoimmunity and inflammatory disease , 2017, Oncotarget.
[65] Jianbing Ma,et al. Dendritic cells should not be overlooked when studying the effect of IL-38 administration in arthritis , 2017, Annals of the rheumatic diseases.
[66] Roberto Giacomelli,et al. Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets , 2017, BMC Rheumatology.
[67] Y. Maehara,et al. Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression , 2017, PloS one.
[68] Hong-yan Zhou,et al. The Effect of Interleukin 38 on Angiogenesis in a Model of Oxygen-induced Retinopathy , 2017, Scientific Reports.
[69] B. Le Goff,et al. IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro , 2017, Annals of the rheumatic diseases.
[70] Jie Dong,et al. In vivo anti-inflammatory activities of novel cytokine IL-38 in Murphy Roths Large (MRL)/lpr mice. , 2017, Immunobiology.
[71] S. Razavi,et al. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy , 2016, Cell journal.
[72] Xiuhe Pan,et al. IL-38 alleviates concanavalin A-induced liver injury in mice. , 2016, International immunopharmacology.
[73] Norbert Meyer,et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. , 2016, The Journal of allergy and clinical immunology.
[74] Renhua Sun,et al. Resolution acute respiratory distress syndrome through reversing the imbalance of Treg/Th17 by targeting the cAMP signaling pathway. , 2016, Molecular medicine reports.
[75] G. Wong,et al. Aberrant Expression of Novel Cytokine IL-38 and Regulatory T Lymphocytes in Childhood Asthma , 2016, Molecules.
[76] M. Li,et al. Production of recombinant human interleukin-38 and its inhibitory effect on the expression of proinflammatory cytokines in THP-1 cells , 2016, Molecular Biology.
[77] J. Ybe,et al. Structural and Functional Attributes of the Interleukin-36 Receptor* , 2016, The Journal of Biological Chemistry.
[78] Yan-fang Jiang,et al. Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B. , 2016, World journal of gastroenterology.
[79] X. Sun,et al. Detection of the novel IL-1 family cytokines by QAH-IL1F-1 assay in rheumatoid arthritis. , 2016, Cellular and molecular biology.
[80] Andrea Schlemmer,et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. , 2016, Journal of molecular cell biology.
[81] R. Laubenbacher,et al. Costimulation Endows Immunotherapeutic CD8 T Cells with IL-36 Responsiveness during Aerobic Glycolysis , 2016, The Journal of Immunology.
[82] Jiaqi Liu,et al. Inflammation and Inflammatory Cells in Myocardial Infarction and Reperfusion Injury: A Double-Edged Sword , 2016, Clinical Medicine Insights. Cardiology.
[83] B. Le Goff,et al. Distinct expression of interleukin (IL)‐36α, β and γ, their antagonist IL‐36Ra and IL‐38 in psoriasis, rheumatoid arthritis and Crohn's disease , 2015, Clinical and experimental immunology.
[84] Kunwu Yu,et al. Elevated Plasma IL-38 Concentrations in Patients with Acute ST-Segment Elevation Myocardial Infarction and Their Dynamics after Reperfusion Treatment , 2015, Mediators of inflammation.
[85] E. Morand,et al. Brief Report: Interleukin‐38 Exerts Antiinflammatory Functions and Is Associated With Disease Activity in Systemic Lupus Erythematosus , 2015, Arthritis & rheumatology.
[86] T. Kinoshita,et al. IL-38: A new factor in rheumatoid arthritis , 2015, Biochemistry and biophysics reports.
[87] S. Tokuyama,et al. Borrelidin Isolated from Streptomyces sp. Inhibited Adipocyte Differentiation in 3T3-L1 Cells via Several Factors Including GATA-Binding Protein 3. , 2015, Biological & pharmaceutical bulletin.
[88] A. Dart,et al. Systemic inflammatory response following acute myocardial infarction , 2015, Journal of geriatric cardiology : JGC.
[89] C. Gabay,et al. Regulation and function of interleukin‐36 cytokines in homeostasis and pathological conditions , 2015, Journal of leukocyte biology.
[90] Yong Li,et al. The ratio of Th17/Treg cells as a risk indicator in early acute respiratory distress syndrome , 2015, Critical Care.
[91] C. Dinarello. Overview of the interleukin-1 family of ligands and receptors. , 2013, Seminars in immunology.
[92] M. Mishina,et al. IL1RAPL1 Associated with Mental Retardation and Autism Regulates the Formation and Stabilization of Glutamatergic Synapses of Cortical Neurons through RhoA Signaling Pathway , 2013, PloS one.
[93] R. Nelson,et al. Hyperlipidemia as a risk factor for cardiovascular disease. , 2013, Primary care.
[94] F. Sallusto,et al. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. , 2012, Blood.
[95] H. Mühl,et al. IL-36γ/IL-1F9, an Innate T-bet Target in Myeloid Cells* , 2012, The Journal of Biological Chemistry.
[96] C. Garlanda,et al. TIR8/SIGIRR is an Interleukin-1 Receptor/Toll Like Receptor Family Member with Regulatory Functions in Inflammation and Immunity , 2012, Front. Immun..
[97] Yong-ming Yao,et al. The role of regulatory T cells in the pathogenesis of sepsis and its clinical implication. , 2012, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[98] P. Barrow,et al. Expression of IL‐1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL‐1F8 and IL‐1F9 , 2012, European journal of immunology.
[99] L. Joosten,et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist , 2012, Proceedings of the National Academy of Sciences.
[100] K. Roeder,et al. Copy Number Variants for Schizophrenia and Related Psychotic Disorders in Oceanic Palau: Risk and Transmission in Extended Pedigrees , 2011, Biological Psychiatry.
[101] H. Dinh,et al. CS16-5. IL-36R Ligands are Potent Regulators of Dendritic and T Cells , 2011 .
[102] R. Tiwari,et al. IL-1R–Associated Kinase-1 Mediates Protein Kinase Cδ-Induced IL-1β Production in Monocytes , 2011, The Journal of Immunology.
[103] M. Iruela-Arispe,et al. Extracellular matrix, inflammation, and the angiogenic response. , 2010, Cardiovascular research.
[104] R. Khalil,et al. Inflammatory cytokines in vascular dysfunction and vascular disease. , 2009, Biochemical pharmacology.
[105] E. Fombonne,et al. Mutations in the calcium-related gene IL1RAPL1 are associated with autism. , 2008, Human molecular genetics.
[106] Hui He,et al. A study on the correlation between IL1RAPL1 and human cognitive ability , 2008, Neuroscience Letters.
[107] A. Grainger. Difficulties in tracking the long-term global trend in tropical forest area , 2008, Proceedings of the National Academy of Sciences.
[108] Y. Humeau,et al. IL1-receptor accessory protein-like 1 (IL1RAPL1), a protein involved in cognitive functions, regulates N-type Ca2+-channel and neurite elongation , 2007, Proceedings of the National Academy of Sciences.
[109] N. Nishimoto. Interleukin-6 in rheumatoid arthritis , 2006, Current opinion in rheumatology.
[110] J. Khan,et al. Crystal Structure of the Toll/Interleukin-1 Receptor Domain of Human IL-1RAPL* , 2004, Journal of Biological Chemistry.
[111] C. Stansberg,et al. The interleukin 1 receptor family. , 2004, Developmental and comparative immunology.
[112] J. Sims,et al. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 Signal through IL-1Rrp2 and IL-1RAcP to Activate the Pathway Leading to NF-κB and MAPKs* , 2004, Journal of Biological Chemistry.
[113] J. Chelly,et al. IL1 receptor accessory protein like, a protein involved in X-linked mental retardation, interacts with Neuronal Calcium Sensor-1 and regulates exocytosis. , 2003, Human molecular genetics.
[114] A. Dunne,et al. The Interleukin-1 Receptor/Toll-Like Receptor Superfamily: Signal Transduction During Inflammation and Host Defense , 2000, Science's STKE.
[115] P. Dawson,et al. Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12-14. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[116] J. E. Ford,et al. Cloning and Characterization of IL-1HY2, a Novel Interleukin-1 Family Member* , 2001, The Journal of Biological Chemistry.
[117] R. Kastelein,et al. Computational identification, cloning, and characterization of IL-1R9, a novel interleukin-1 receptor-like gene encoded over an unusually large interval of human chromosome Xq22.2-q22.3. , 2000, Genomics.
[118] M. Rischmueller,et al. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. , 2000, Arthritis and rheumatism.
[119] F. Muntoni,et al. Two novel members of the interleukin-1 receptor gene family, one deleted in Xp22.1–Xp21.3 mental retardation , 2000, European Journal of Human Genetics.
[120] T. Born,et al. Identification and characterization of two members of a novel class of the interleukin-1 receptor (IL-1R) family. Delineation of a new class of IL-1R-related proteins based on signaling. , 2000, The Journal of biological chemistry.
[121] Lin Jun,et al. A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation , 1999, Nature Genetics.
[122] J. Sims,et al. Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. , 1999, Cytokine.
[123] C. Janeway,et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. , 1998, Molecular cell.
[124] I. M. Neiman,et al. [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.